“…Following the demonstration that this SNP was functionally relevant over the past 18 years, more than 1700 studies have investigated the effects of this polymorphism on brain function in health, as well as in diseases, particularly in neuropsychiatric disorders [ 115 , 116 ]. The BDNF Val66Met polymorphism has been associated with cerebral cortex plasticity [ 117 , 118 ], with gray matter structures [ 119 , 120 ], or white matter integrities and structural networks [ 121 , 122 ]. More specifically, BDNF Val66Met polymorphism is associated with cognitive processes [ 112 , 123 , 124 , 125 , 126 , 127 ], and cognitive impairment in neurodegenerative disease, such as Parkinson’s disease (PD) [ 128 , 129 ] and AD [ 130 , 131 ], and even more with several brain disorders, including MDD and bipolar disorder [ 132 , 133 , 134 , 135 , 136 , 137 ], epilepsy [ 138 , 139 , 140 ], schizophrenia [ 125 , 141 , 142 , 143 , 144 ], aging and dementia [ 145 ] and stroke [ 117 , 146 , 147 ].…”